This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR delayed release capsules of AstraZeneca Pharmaceuticals LP.

Esomeprazole is used to treat certain stomach and esophagus problems (such as acid reflux and ulcer). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers and is expected to help prevent cancer of the esophagus. Esomeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

"The product will be manufactured at the Company's formulation manufacturing facility in Goa, India,” Marksans Pharma said in a statement.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

On consolidated basis, the company's net profit jumped 15% to Rs 68.66 crore during the quarter as compared with Rs 59.72 crore posted in corresponding quarter last year. Net sales increased 15.3% year on year to Rs 500.03 crore in Q1 FY24 over Q1 FY23.

The scrip shed 0.86% to currently trade at Rs 109 on the BSE.